KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Gains from Sales and Divestitures (2016)

AbbVie (ABBV) has disclosed Gains from Sales and Divestitures for 4 consecutive years, with $6.1 million as the latest value for Q2 2016.

  • On a quarterly basis, Gains from Sales and Divestitures rose 11.16% to $6.1 million in Q2 2016 year-over-year; TTM through Jun 2016 was $6.1 million, a 11.16% increase, with the full-year FY2015 number at $5.7 million, down 14.1% from a year prior.
  • Gains from Sales and Divestitures was $6.1 million for Q2 2016 at AbbVie, up from $5.5 million in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $7.6 million in Q4 2013 to a low of $5.3 million in Q1 2015.
  • A 4-year average of $6.4 million and a median of $6.3 million in 2014 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: dropped 14.53% in 2015, then grew 11.16% in 2016.
  • AbbVie's Gains from Sales and Divestitures stood at $7.6 million in 2013, then fell by 12.11% to $6.6 million in 2014, then fell by 14.1% to $5.7 million in 2015, then rose by 7.65% to $6.1 million in 2016.
  • Per Business Quant, the three most recent readings for ABBV's Gains from Sales and Divestitures are $6.1 million (Q2 2016), $5.5 million (Q1 2016), and $5.7 million (Q4 2015).